Fulgent Genetics(US:FLGT)2025-08-01 12:30Financial Performance - Fulgent Genetics' Q2 2025 core revenue reached $82 million, a 16% year-over-year increase [12, 13] - The company's last twelve months (LTM) core revenue as of Q2 2025 was $3029 million, a 14% year-over-year increase [81] - Q2 2025 gross profit was $34435 thousand, with a gross margin of 421% [85, 88] - Non-GAAP gross profit for Q2 2025 was $36036 thousand, resulting in a non-GAAP gross margin of 441% [87, 90] - The company anticipates approximately $770 million in cash, cash equivalents, and investments in marketable securities as of December 31, 2025 [92] Financial Guidance - Fulgent Genetics projects a full-year 2025 core revenue of $320 million, representing a 14% year-over-year growth [92] - The company expects a GAAP EPS of ($210) and a non-GAAP EPS of ($035) for the full year 2025 [92] - The revenue breakdown for 2025 is projected as follows: Precision Diagnostics at $194 million, Anatomic Pathology at $108 million, and BioPharma Services at $18 million [92] Therapeutic Development - FID-007, a wholly-owned drug candidate, is initially focused on Head & Neck (H&N) and Pancreatic/Ampullary cancers [76] - Preliminary findings from the FID-007 Phase 1/1b clinical trial showed a 45% ORR and 72% DCR in heavily treated HNSCC patients [61] - The Phase 2 trial for FID-007 plus Cetuximab in H&N cancer has multiple clinical sites activated with 32 patients dosed as of August 1, 2025 [62] - The market opportunity for Head & Neck cancer is estimated at $186 billion in 2025, growing to $21 billion by 2035 [19, 72]